Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2025; 17(9): 109179
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109179
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109179
Evaluating thresholds of Mac-2 binding protein glycosylation isomer in association with clinical outcomes in patients with cirrhosis
Trung Hieu Doan, Xung Van Nguyen, Department of Gastroenterology, Danang Hospital, Danang 50000, Viet Nam
Khue Minh Nguyen, Department of Genetics, Ho Chi Minh University of Science, Ho Chi Minh City 700000, Viet Nam
Khue Minh Nguyen, Department of Scientific Affairs, Sysmex Vietnam, Ho Chi Minh City 700000, Viet Nam
Anh Thi Ngoc Pham, Department of Laboratory, Danang Hospital, Danang 50000, Viet Nam
Nhan Duc Le, Intensive Care Unit, Danang Hospital, Danang 50000, Viet Nam
Co-first authors: Trung Hieu Doan and Khue Minh Nguyen.
Author contributions: Doan TH and Nguyen KM contributed to the design of the study, revised the collected data, performed the statistical data analysis and interpretation, and reviewed and provided the final version of the manuscript; Nguyen XV and Pham ATN shared the operational work of the study and the writing of the manuscript; Doan TH and Nguyen XV recruited participants and collected data; Le ND supervised the study; Doan TH and Nguyen KM contributed equally to this study and merit co-first authorship; all authors contributed to revision of the manuscript for important intellectual content and approved the final version.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of the Da Nang Hospital (No. 2022.11.54 issued in March 2022).
Informed consent statement: Informed consent was waived for this study based upon the utilization of residual blood samples.
Conflict-of-interest statement: Khue Minh Nguyen is a Sysmex employee. All other authors declare no conflicts of interest.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Data sharing statement: Technical appendix, statistical code, and dataset available from the co-first authors at minhkhuenguyen8888@gmail.com or drdoanhieutrungbvdn@gmail.com. No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nhan Duc Le, MD, PhD, Intensive Care Unit, Danang Hospital, 124 Hai Phong, Hai Chau, Danang 50000, Viet Nam. drnhandanang@gmail.com
Received: May 8, 2025
Revised: June 28, 2025
Accepted: August 21, 2025
Published online: September 27, 2025
Processing time: 141 Days and 8.5 Hours
Revised: June 28, 2025
Accepted: August 21, 2025
Published online: September 27, 2025
Processing time: 141 Days and 8.5 Hours
Core Tip
Core Tip: This study introduces serum mac-2 binding protein glycosylation isomer (M2BPGi) as a novel biomarker for predicting complications in cirrhotic patients, particularly hepatocellular carcinoma (HCC), liver decompensation, and esophageal varices. The findings show that combining M2BPGi with alpha-fetoprotein significantly enhances diagnostic accuracy, achieving an impressive sensitivity of 92.8% for HCC detection. Importantly, M2BPGi levels correlate with disease severity as measured by the Child-Pugh classification, highlighting its potential role in clinical risk stratification.